[
    [
        {
            "time": "2018-07-01",
            "original_text": "Novartis’s Quarterly Revenue Trend in Q2 2018",
            "features": {
                "keywords": [
                    "Novartis",
                    "Quarterly Revenue",
                    "Q2",
                    "2018"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Novartis’s Quarterly Revenue Trend in Q2 2018",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 3,
                "Headline_Structure": 5,
                "Source_Recency": 2
            }
        },
        {
            "time": "2018-08-15",
            "original_text": "25 Dividend Stocks That Analysts Love the Most",
            "features": {
                "keywords": [
                    "Dividend Stocks",
                    "Analysts",
                    "Love"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "dividends"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "25 Dividend Stocks That Analysts Love the Most",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-06-20",
            "original_text": "Pfizer's Tafamidis Fails to Impress in Cardiomyopathy Study",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Tafamidis",
                    "Cardiomyopathy",
                    "Study",
                    "Fails"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Pfizer's Tafamidis Fails to Impress in Cardiomyopathy Study",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-08-10",
            "original_text": "Novartis’s Valuation in August",
            "features": {
                "keywords": [
                    "Novartis",
                    "Valuation",
                    "August"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Novartis’s Valuation in August",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 4,
                "Headline_Structure": 5,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-06-20",
            "original_text": "Pfizer's Tafamidis Fails to Impress in Cardiomyopathy Study",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Tafamidis",
                    "Cardiomyopathy",
                    "Study",
                    "Fails"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Pfizer's Tafamidis Fails to Impress in Cardiomyopathy Study",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]